Chugai sales and marketing update

Chugai launched Perjeta pertuzumab in Japan to treat HER2-positive inoperable or recurrent breast cancer. The Japanese National Health Insurance (NHI) list price is ¥231,866 ($2,331) for a 420 mg/14 mL vial. The dosing, when used in combination with Herceptin trastuzumab and other anticancer drugs, consists of a loading dose of 840 mg of pertuzumab followed by 420 mg every three weeks. ...